The MSD platform offers significant advantages to detect and quantify protein and protein-complexes in complex matrices such as human serum/plasma or tissue homogenates. These include:
There are a number of approaches that can be taken to develop assays to detect the complex between IPF and gp-41 or gp-120. IPF and specific cancer antigen target. One approach would be to obtain specific antibodies against IPF and specific ovarian cancer antigen and to build a sandwich immunoassay to detect the presence of these protein complexes. Second approach would be to obtain specific antibodies against IPF and gp 41 or gp 120, or if you are looking to detect the binding of gp-120 or gp-41 to IPF, the antigen can be coated on a plate to capture proteins from the sample and then report the binding with a specific detection antibody. e.g.
The secondary (or detection) antibody can be directly labeled with MSD SULFO-TAG NHS ester or you can use a SULFO-TAG labeled anti-species antibody e.g. anti-mouse if the detection antibody is raised in mouse and provided that the detection antibody is raised in a different species than the capture (or primary) antibody.
You can also use antibodies specific to the ovarian cancer antigen complex IPF- gp -120 or IPF-gp-41 complexes for this purpose.
As with all immunoassays the sensitivity and performance of the assay with be driven by the specificity and affinity of the antibodies used in the assay.
In addition to implementing assays specific to the antigen complex, the MSD platform also enables to easily measure a wide range of biomarkers in patient samples e.g. up to cytokines simultaneously with only 25 ul of sample.